TGFBI

Across TCGA pan-cancer cohorts, TGFBI mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TGFBI data layer compared with 25 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TGFBI mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated TGFBI expression acts as an unfavorable survival marker.

CCRCC, LUAD, and GBM are the cancer types where TGFBI mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	II,III,IV	0.128	0.952	.003	37	view →
LUAD	OS	Quartile	II,III,IV	0.451	1.000	.003	20	view →
GBM	DFS	Tertile	All	0.158	0.366	.022	14	view →
LSCC	DFS	Quartile	II,III,IV	0.587	1.000	.004	10	view →
PDAC	DFS	Median	III,IV	0.490	0.882	.005	8	view →
HNSC	DFS	Median	All	0.555	0.724	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TGFBI–CCRCC (DFS)

Open the CCRCC breakdown →